Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production
06 Jul 2022
Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production
ANN ARBOR, Mich., July 06, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production.
With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.
The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30-100% larger silk cocoons than non-hybridized silkworms.
The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today's announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.
"The hybridization program was a key part of the Company's technology roadmap and something our R&D team has been quietly working on behind the scenes," said Company COO Jon Rice. "Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line."
Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company's success with 3rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.